Poland· PL-100425067
Giapreza
A angiotensin ii product containing angiotensinamidum, registered in Poland by PAION Pharma GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Angiotensin ii is registered in 11 of 19 countries.
Countries holding a registration under ATC C01CX09 (angiotensin ii), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Angiotensin ii · ATC C01CX09
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Angiotensinamidum
- Manufacturer
- PAION Pharma GmbH
- Country
- Poland (PL)
- ATC code
- C01CX09
- ATC class
- Angiotensin II
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04260727580285
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under C01CX09
Angiotensin ii, as other registers publish it.
- United StatesANGIOTENSIN IIGland Pharma Limited
- FinlandGiaprezaPAION Pharma GmbH
- United StatesGiaprezaLa Jolla Pharmaceutical Company
- IcelandGiaprezaPAION Pharma GmbH
- United StatesGiaprezaLa Jolla Pharmaceutical Company
- United StatesGiaprezaLa Jolla Pharmaceutical Company
- United StatesGiaprezaLa Jolla Pharmaceutical Company
- DenmarkGiaprezaPAION Deutschland GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eafeac9e-0a84-4e0e-86f3-7f6b0e057cef GET /v1/drugs/eafeac9e-0a84-4e0e-86f3-7f6b0e057cef?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "2,5 mg/ml",
"packaging": "Rpz ¦ EU/1/19/1384/001 ¦ 134101\n1 fiol. \nRpz ¦ EU/1/19/1384/002 ¦ 134102\n1 fiol. \n04260727580285 ¦ Rpz ¦ EU/1/19/1384/003 ¦ 148866\n10 fiol. 1 ml",
"substance": "Angiotensinamidum 2.5 mg/ml",
"common_name": "Angiotensinamidum",
"pl_product_id": "100425067",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about angiotensin ii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.